中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.021 seconds)

    PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES
    1.
    发明申请
    PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES 审中-公开
    用于治疗病毒性疾病的吡嗪衍生物

    公开(公告)号：WO0107027A3

    公开(公告)日：2001-08-09

    申请号：PCT/US0019650

    申请日：2000-07-19

    Applicant: VERTEX PHARMA ,  HALE MICHAEL ,  MALTAIS FRANCOIS ,  BAKER CHRISTOPHER ,  JANETKA JAMES ,  MOON YOUNG CHOON ,  SAUNDERS JEFFREY

    Inventor： HALE MICHAEL ,  MALTAIS FRANCOIS ,  BAKER CHRISTOPHER ,  JANETKA JAMES ,  MOON YOUNG CHOON ,  SAUNDERS JEFFREY

    IPC: A61K31/505 ,  A61K45/06 ,  A61K31/506 ,  A61K31/513 ,  A61P31/12

    CPC classification number: A61K31/505 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to a method useful for inhibiting viral helicases, and in particular, the hepatitis C virus NS3 helicase. The method employs compositions having formula (I) where R , R , R , R , X and T are as described herein. Preferred compounds are those where R is an electron withdrawing group such as halo, CN or CO2R . More preferred are those compounds where R is an electron withdrawing group and R is OH. Most preferred are those compounds where R and R are as just described and X is S. In particular, the compositions and methods of this invention are useful in treating diseases caused by hepatitis C virus, bovine viral diarrhea virus or vaccinia virus.

    Abstract translation: 本发明涉及用于抑制病毒解旋酶，特别是丙型肝炎病毒NS3解旋酶的方法。 该方法使用具有式（I）的组合物，其中R 1，R 2，R 3，R 4，X和T如本文所述。 优选的化合物是其中R 3是吸电子基团如卤素，CN或CO 2 R 1的化合物。 更优选的是其中R 3为吸电子基团且R 2为OH的那些化合物。 最优选的是其中R 2和R 3如上所述且X是S的化合物。特别地，本发明的组合物和方法可用于治疗由丙型肝炎病毒，牛病毒性腹泻病毒或 牛痘病毒

    Phenyl derivative useful as inhibitors of IMPDH enzyme
    7.
    发明专利
    Phenyl derivative useful as inhibitors of IMPDH enzyme 未知

    公开(公告)号：NZ514540A

    公开(公告)日：2003-11-28

    申请号：NZ51454000

    申请日：2000-03-17

    Applicant: VERTEX PHARMA

    Inventor： STAMOS DEAN ,  TRUDEAU MARTIN ,  BETHIEL SCOTT ,  BADIA MICHAEL ,  SAUNDERS JEFFREY

    IPC: C07D307/20 ,  A61K31/27 ,  A61K31/275 ,  A61K31/341 ,  A61K31/421 ,  A61K31/422 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/00 ,  A61P1/18 ,  A61P9/10 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07C275/40 ,  C07C275/42 ,  C07D263/32 ,  C07D413/12 ,  C07D417/12 ,  C07F9/653 ,  C07C275/34

    Abstract: A phenyl derivative has the formula (A) wherein: each of R1 and R2 is independently hydrogen, -CF3, alkyl, alkenyl, alkynyl, alkyl-R7, alkenyl-R7, alkynyl-R7 or -R7, provided at least one of R1 or R2 is alkyl-R7, alkenyl-R7, alkynyl-R7 or -R7; wherein up to 4 hydrogen atoms in any of the alkyl, alkenyl or alkynyl are optionally replaced by R3, or one or both of R1 or R2 are optionally esterified to form a prodrug or R1 and R2 are alternatively taken together to form tetrahydrofuranyl, when R9 is hydrogen, (R)-methyl, (R)- ethyl or (R)-hydroxymethyl, one hydrogen atom in the tetrahydrofuran is replaced by -OR6 or -R7, and when R9 is (S)- methyl, (S)-ethyl or (S)-hydroxymethyl, one hydrogen atom in the tetrahydrofuran is optionally replaced by -OR6 or -R7 or when R9 is hydrogen, (R)-methyl, (R)-ethyl or (R)- hydroxymethyl and each of R1 and R2 are independently hydrogen, unsubstituted alkyl, or unsubstituted alkenyl or alkynyl, then the portion of the compound represented by - CH(R1)R2 is a C5-12 alkyl, alkenyl or alkynyl; each R3 is independently halo, CN, -OR4, or -N(R5)2; R4, R5, R6 and R8 are as defined in the specification, each R7 is a monocyclic or bicyclic ring system wherein each ring system comprises 3 to 7 ring atoms independently selected from C, N, O and S, no more than 4 ring atoms are selected from N, O or S, any CH2 is optionally replaced with C (O) and any S is optionally replaced with S(O) or S(O)2; R9 is hydrogen, (R)-methyl, (S)-methyl, (R)-ethyl, (S)- ethyl, (R)-hydroxymethyl or (S)-hydroxymethyl; R10 is -C=N or 5-oxazolyl, and R11 is halo, -O-alkyl, or -O-alkenyl or -O-alkynyl. The compounds are useful for treating or preventing an inosine-5'-monophosphate dehydrogenase disease or condition.

Patent Agency Ranking